OncoZenge: First patient enrolled in Pivotal Phase III Study - Redeye

Redeye comments on OncoZenge’s announcement that the first patient has been enrolled in the pivotal Phase III BEAM-Pain trial of BupiZenge. We view this as a major operational milestone, marking the company's successful transition from regulatory preparation to clinical execution and bringing BupiZenge another important step closer to potential market approval in Europe.

Länk till analysen i sin helhet: https://www.redeye.se/research/1173391/oncozenge-first-patient-enrolled-in-pivotal-phase-iii-study?utm_source=finwire&utm_medium=RSS